Fiche personne
Territoire
Alsace
Statut
Hospitalier
Publications
Real-world outcomes of metastatic cancer patients hospitalized at initial diagnosis: ONIRIS, a national study.
Vercueil C, Varnier R, Seban R, Ciaptacz L, Pavillet J, Fraisse C, Darbas T, Abdallahoui S, Cox D, Martin S, Trensz P, Kurtz JE, Gantzer J, Amé S, Bouleuc C, Chvetzoff G, Eberst L
Support Care Cancer. 2025 02 3;33(2):145
Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice.
Amé S, Barraco F, Ianotto JC, Jourdan E, Rey J, Viallard JF, Wémeau M, Kiladjian JJ
EJHaem. 2023 08;4(3):779-791
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Balsat M, Alcazer V, Etienne G, Huguet F, Berger M, Cayssials E, Charbonnier A, Escoffre-Barbe M, Johnson-Ansah H, Legros L, Roy L, Delmer A, Ianotto JC, Orvain C, Larosa F, Meunier M, Amé S, Andreoli A, Cony-Makhoul P, Morisset S, Tigaud I, Rea D, Nicolini FE
Leuk Res. 2023 05 9;130:107308
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Roy L, Chomel JC, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, Charbonnier A, Dubruille V, Huguet F, Johnson-Ansah H, Lenain P, Ame S, Etienne G, Nicolini FE, Rea D, Cony-Makhoul P, Courby S, Ianotto JC, Legros L, Machet A, Coiteux V, Hermet E, Cayssials E, Bouchet S, Mahon FX, Rousselot P, Guilhot F,
Br J Haematol. 2022 10 10;:
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Mekinian A, Zhao LP, Chevret S, Desseaux K, Pascal L, Comont T, Maria A, Peterlin P, Terriou L, D'Aveni Piney M, Gourin MP, Vey N, Rauzy OB, Grobost V, Bezanahary H, Dimicoli-Salazar S, Banos A, Wickenhauser S, De Renzis B, Durot E, Natarajan-Amé S, Voillat L, Chermat F, Lemaire K, Jachiet V, Himberlin C, Thépot S, Diaz JMT, Frenzel L, Gyan E, Denis G, Hirsch P, Kosmider O, Ades L, Fain O, Fenaux P
Leukemia. 2022 09 14;:
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.
Jachiet V, Ricard L, Hirsch P, Malard F, Pascal L, Beyne-Rauzy O, Peterlin P, Maria ATJ, Vey N, D'Aveni M, Gourin MP, Dimicoli-Salazar S, Banos A, Wickenhauser S, Terriou L, De Renzis B, Durot E, Natarajan-Ame S, Vekhoff A, Voillat L, Park S, Vinit J, Dieval C, Dellal A, Grobost V, Willems L, Rossignol J, Solary E, Kosmider O, Dulphy N, Zhao LP, Adès L, Fenaux P, Fain O, Mohty M, Gaugler B, Mekinian A,
Clin Exp Med. 2022 08 11;:
Innovative approach to lymphadenectomy in breast sarcoma.
Ramelli E, Weingertner N, Welsch A, Reix N, Antoni D, Amé S, Molière S, Mathelin C
Bull Cancer. 2022 06 15;:
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Adès L, Duployez N, Guerci-Bresler A, Laribi K, Peterlin P, Vey N, Thepot S, Wickenhauser S, Zerazhi H, Stamatoullas A, Wattel E, Recher C, Toma A, Dimicoli-Salazar S, Braun T, Beyne-Rauzy O, Marolleau JP, Cheze S, Park S, Cluzeau T, Nimubona S, Bordessoule D, Benramdane R, Quesnel B, Amé S, de Botton S, Chermat F, Preudhomme C, Chevret S, Fenaux P
Br J Haematol. 2022 Apr 19;:
A New Modality for Breast Cancer Diagnosis During the COVID-19 Pandemic: A Case Report.
Vibert F, Martel C, Ionescu RA, Mathelin C, Ame S
Eur J Breast Health. 2022 Jan;18(1):91-93
Protective role of melatonin in breast cancer: what we can learn from women with blindness.
Minella C, Coliat P, Amé S, Neuberger K, Stora A, Mathelin C, Reix N
Cancer Causes Control. 2021 Nov 27;:
New Data on the Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma.
Ionescu P, Vibert F, Amé S, Mathelin C
Eur J Breast Health. 2021 Oct;17(4):302-307
Breast Cancer Management During the COVID-19 Pandemic: The Senologic International Society Survey.
Mathelin C, Ame S, Anyanwu S, Avisar E, Boubnider WM, Breitling K, Anie HA, Conceição JC, Dupont V, Elder E, Elfgen C, Elonge T, Iglesias E, Imoto S, Ioannidou-Mouzaka L, Kappos EA, Kaufmann M, Knauer M, Luzuy F, Margaritoni M, Mbodj M, Mundinger A, Orda R, Ostapenko V, Özbaş S, Özmen V, Pagani O, Pieńkowski T, Schneebaum S, Shmalts E, Selim A, Pavel Z, Lodi M, Maghales-Costa M
Eur J Breast Health. 2021 Apr;17(2):188-196
Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib.
Levêque D, Becker G, Bilger K, Natarajan-Amé S
Clin Pharmacokinet. 2020 Feb 29;:
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M
Haematologica. 2019 Mar;104(3):497-504
Tuberculosis and atypical mycobacterial infections in ruxolitinib treated patients with primary or secondary myelofibrosis or polycythemia vera.
Lescuyer S, Ledoux MP, Gravier S, Natarajan-Amé S, Duval C, Maloisel F, Mauvieux L, Toussaint E, Fornecker LM, Herbrecht R
Int. J. Infect. Dis.. 2019 Jan 10;:
Ponatinib Evaluation And safety in Real Life CML patients failing ≥2 tyrosine kinase inhibitors: The PEARL observational study.
Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE
Exp. Hematol.. 2018 Sep 5;:
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX,
Cancer. 2018 May 3;:
Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low-risk MDS and iron overload.
Rose C, Lenoir C, Gyan E, Hacini M, Amé S, Corront B, Beyne-Rauzy O, Adiko D, Loppinet E, Ali-Ammar N, Laribi K, Wattel E, Dreyfus F, Roué CS, Cheze S
Eur. J. Haematol.. 2018 May 2;:
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
Díez-Campelo M, Lorenzo JI, Itzykson R, Rojas SM, Berthon C, Luño E, Beyne-Rauzy O, Perez-Oteyza J, Vey N, Bargay J, Park S, Cedena T, Bordessoule D, Muñoz JA, Gyan E, Such E, Visanica S, López-Cadenas F, de Botton S, Hernández-Rivas JM, Ame S, Stamatoullas A, Delaunay J, Salanoubat C, Isnard F, Guieze R, Pérez Guallar J, Badiella L, Sanz G, Cañizo C, Fenaux P
Br. J. Haematol.. 2018 05;181(3):350-359
A single-nucleotide polymorphism of ABCB1 (MDR1) is correlated with poor response to Imatinib chronic myeloid leukemia.
Glady L, Guerin E, Ame S, Maloisel F, Lessinger JM
Ann. Oncol.. 2017 Oct;28 Suppl 7:vii5-vii6
Adherence and patients' attitudes to oral anticancer drugs: a prospective series of 201 patients focusing on targeted therapies.
Barthelemy P, Asmane-De la Porte I, Meyer N, Duclos B, Serra S, Dourthe LM, Ame S, Litique V, Giron C, Goldbarg V, Fornecker L, Quoix E, Kurtz JE
Oncology. 2015;88(1):1-8
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.
Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Amé S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX
Lancet Haematol. 2015 Jan;2(1):e37-46
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Prebet T, Braun T, Beyne-Rauzy O, Dreyfus F, Stammatoullas A, Wattel E, Ame S, Raffoux E, Delaunay J, Charbonnier A, Ades L, Fenaux P, Vey N
Leuk Res. 2014 Jan;38(1):29-33
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
Santini V, Schemenau J, Levis A, Balleari E, Sapena R, Ades L, Guerci A, Beyne-Rauzy O, Gourin MP, Cheze S, Stamatoullas A, Sanna A, Gioia D, Cametti G, Ferrero D, Raffoux E, Rose C, Poloni A, Prebet T, Legros L, Natarajan-Ame S, Fenaux P, Germing U, Dreyfus F, Park S
Blood. 2013 Sep 26;122(13):2286-8
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Ades L, Pillard F, Lamberto C, Charniot JC, Guerci A, Choufi B, Stamatoullas A, Slama B, De Renzis B, Ame S, Damaj G, Boyer F, Chaury MP, Legros L, Cheze S, Testu A, Gyan E, Bene MC, Rose C, Dreyfus F, Fenaux P
Ann Hematol. 2013 May;92(5):621-31
Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease.
Antoni D, Natarajan-Ame S, Meyer P, Niederst C, Bourahla K, Noel G
Radiat Oncol. 2013 May 2;8:112
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Natarajan-Ame S, Park S, Ades L, Vey N, Guerci-Bresler A, Cahn JY, Etienne G, Bordessoule D, Ravoet C, Legros L, Cheze S, Stamatoullas A, Berger E, Schmidt A, Charbonnier A, Chaury MP, Braun T, Fenaux P, Dreyfus F
Br J Haematol. 2012 Jul;158(2):232-7
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
Itzykson R, Thepot S, Beyne-Rauzy O, Ame S, Isnard F, Dreyfus F, Salanoubat C, Taksin AL, Chelgoum Y, Berthon C, Malfuson JV, Legros L, Vey N, Turlure P, Gardin C, Boehrer S, Ades L, Fenaux P
Leuk Res. 2012 Apr;36(4):397-400
Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level.
Legros L, Slama B, Karsenti JM, Vey N, Natarajan-Ame S, Watel E, Richard B, Bouabdallah K, Mannone L, Benchetrit M, Touitou I, Huault S, Durivault J, Ambroseti D, Hueber AO, Fenaux P, Dreyfus F
Ann Hematol. 2012 Jan;91(1):39-46
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.
Park S, Sapena R, Kelaidi C, Vassilieff D, Bordessoule D, Stamatoullas A, Cheze S, Beyne-Rauzy O, Vey N, Rose C, Guerci A, Natarajan-Ame S, Tertian G, Slama B, Fenaux P, Dreyfus F
Leuk Res. 2011 Nov;35(11):1530-3
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.
Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, de Botton S, Chelghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Ades L, Fenaux P
Blood. 2011 Jan 13;117(2):403-11
Factors associated with overall and attributable mortality in invasive aspergillosis.
Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C, Lioure B, Bilger K, Lutun P, Marcellin L, Launoy A, Freys G, Bergerat JP, Herbrecht R
Clin Infect Dis. 2008 Nov 1;47(9):1176-84
Invasive aspergillosis in the hematologic and immunologic patient: new findings and key questions in leukemia.
Herbrecht R, Moghaddam A, Mahmal L, Natarajan-Ame S, Fornecker LM, Letscher-Bru V
Med Mycol. 2005 May;43 Suppl 1:S239-42.
Can combination salvage therapy for invasive aspergillosis improve patient outcome?
Herbrecht R, Natarajan-Ame S
Nat Clin Pract Oncol. 2005 Apr;2(4):186-7.
